AzTrials
AzTrials

Heart FailureNCT04977310

TARGET-LOAD Pilot Study Comparing Hemodynamics-guided LVAD Unloading Vs. Standard of Care

A study testing CardioMEMS in people with Heart Failure, run by STAVROS G DRAKOS at 2 sites in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This study is a prospective, randomized-controlled, non-blinded, multi-center, pilot trial to compare standard-of-care left ventricular assist device (LVAD) unloading plus heart failure (HF) medications reverse-remodeling management versus hemodynamics-guided LVAD unloading with use of the wireless monitoring system… Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Heart Failure
What is being tested?
CardioMEMS
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
2 sitesUnited States
Study dates
31 Mar 2025to 1 Sep 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Severe clinical HF resistant to intensive medical therapy and requiring LVAD implantation
  • Left ventricular ejection fraction <=25% and cardiomegaly at time of LVAD implantation
  • Non-ischemic etiology of HF
  • Undergone LVAD implantation within prior 4 weeks or planned for LVAD implant
  • History of HF < 5 years
  • Body Mass Index <=35 kg/m^2
  • Pulmonary artery branch diameter between 7 - 15 mm
  • Female subjects of childbearing age with negative urine or serum pregnancy test and agreeing to use reliable mechanical or hormonal form of contraception during study

Who cannot join

  • Evidence of active acute myocarditis confirmed by histology
  • History of previous cerebrovascular accident resulting in significant fixed motor deficit, limiting ability to perform exercise testing
  • Implanted mechanical aortic and/or mitral valve(s) and/or right heart valve(s)
  • Aortic valve closure
  • Hypertrophic obstructive cardiomyopathy or sarcoidosis
  • Left ventricular end-diastolic diameter below normal (restrictive cardiomyopathy)
Show all 19Show fewer
  • Irreversible multi-organ failure
  • Diagnosis of psychiatric disease, irreversible cognitive dysfunction or poor psycho-social issues likely to impair compliance with study protocol
  • Any condition that could limit survival to less than 2 years
  • History of cardiac or other organ transplant
  • Contraindicated to anti-coagulation, antiplatelet therapy, or diagnosis of coagulation disorders
  • Require acute or chronic renal replacement therapy within 3 months prior to enrollment
  • Participation in any other clinical investigations involving another Mechanical Circulating Support device or HF-related drug
  • Active infection
  • History of recurrent (>1) pulmonary embolism or deep vein thrombosis
  • Unable to tolerate right heart catheterization
  • Implantation of cardiac re-synchronization therapy < 3 months before enrollment
  • Congenital heart disease
  • Hypersensitivity or allergy to aspirin and/or clopidogrel

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Inova Heart and Vascular Institute

    Falls Church, Virginia, 22042

  • University of Kentucky

    Lexington, Kentucky, 40536

Other trials in United States

About this study

Official title: Prospective, Randomized-controlled, Non-blinded, Multi-center, Pilot Trial to Compare Standard-of-care LVAD Unloading Plus Heart Failure Medications Reverse-modeling Management Versus Hemodynamics-guided LVAD Unloading with the Use of the Wireless Monitoring System CardioMEMS Plus Heart Failure Medications Reverse-remodeling Management

This study is a prospective, randomized-controlled, non-blinded, multi-center, pilot trial to compare standard-of-care left ventricular assist device (LVAD) unloading plus heart failure (HF) medications reverse-remodeling management versus hemodynamics-guided LVAD unloading with use of the wireless monitoring system CardioMEMS plus HF medications reverse-remodeling management.

Read the detailed description

LVADs are being increasingly used in end-stage heart failure patients as a bridge to transplant (BTT) or as a destination therapy (DT). Although LVAD recipients are considered to be optimally unloaded with speed optimizations following LVAD implantation, re-hospitalizations due to HF recurrence are far from negligible. Recent studies have reported that at least 35% of hospital readmissions post-LVAD implantation are due to HF exacerbations, volume status changes or other cardiac causes (arrhythmias etc.). This suggests that patients are being sub-optimally unloaded and/or taking inadequate medical therapy and probably this decreases the chances for potential reverse remodeling and myocardial recovery. Moreover, a recent study demonstrated that cardiac dimensions obtained from echocardiography do not adequately reflect the degree of mechanical unloading of the heart. It has also shown strong evidence that pulmonary artery (PA) pressures monitoring can be reliably used to assess the pulmonary capillary wedge pressure (PCWP) and left ventricular end-diastolic pressure (LVEDP).

Symptomatic heart failure exacerbation requiring hospital admission may lie at the end of a spectrum of worsening hemodynamics that are unable to be detected before the manifestation of symptoms and limits the potential for myocardial recovery. Therefore, it is proposed that repeatedly adjusting LVAD pump flow speed and tailoring standard HF medications depending on the patient's PA pressure acquired from the CardioMEMS device can optimize pressure and volume unloading and promote reverse cardiac remodeling and recovery.

Clinical experience with LVAD support has shown that a subset of LVAD patients can experience reverse cardiac remodeling and significant improvement of myocardial function suggesting that LVAD-induced mechanical unloading of the failing heart may be a plausible therapeutic strategy aiming at myocardial recovery and device removal. These explanted patients have shown "myocardial plasticity" in clinical studies and that they can be responsive and sensitive to load changes. These patients will be carefully monitored to prevent increased load and wall stress to drive again the detrimental spiral of cardiac remodeling and HF recurrence, which appears to be the case in at least one third of LVAD patients after device weaning. Along the same lines, the results from another clinical study showed a significant and large reduction in hospitalization for HF patients who were managed with CardioMEMS. Therefore, further improvement of patients' HF management will depend mainly on better identification and pro-active management of their fluid and hemodynamic status. It is proposed that chronically adjusting HF medications using CardioMEMS-guided hemodynamic assessment in patients who have weaned from LVAD support could improve long-term durability of cardiac improvement after LVAD weaning.

Conditions
Heart Failure
Being tested
CardioMEMS
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CardioMEMSDevice

    Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery

Study groups in NCT04977310
Study groupRoleWhat they receive
ControlNo interventionAfter LVAD implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using echocardiographic imaging and other standard-of-care practices. During the Unloading phase, patients are serially evaluated with echocardiograms to assess for cardiac recovery, and LVAD explantation performed when predefined criteria are met. After explantation, patients undergo cardiac rehab and regular follow up.
InterventionExperimentalAfter LVAD and wireless monitoring system (CardioMEMS) implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using CardioMEMS. During the Unloading phase, invasive hemodynamic guidance (via CardioMEMS) will be utilized to optimize pressure and volume unloading along with serial echocardiographic evaluations to assess for cardiac recovery, and LVAD explantation will be considered. After explantation, patients will undergo cardiac rehab and regular follow up with adjustments of HF medications based on the CardioMEMS-guided hemodynamic assessment.
Receives: Device: CardioMEMS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of subjects that meet explantation criteria by month 12 post-LVAD implantation, have LVAD explanted and retain left ventricular ejection fraction >=45% at 12 months post-LVAD weaning

    Removal of LVAD happens when subject meets all five of the following explantation criteria: (1) left ventricular end-diastolic diameter < 60mm; (2) left ventricular end-systolic diameter < 50mm; (3) left ventricular ejection fraction > 45%; (4) left ventricular end-diastolic pressure <= 15 mmHg; (5) resting cardiac index > 2.4 L/min/m^2

    Measured: 24 months

Secondary outcomes (2)
  1. Hospital Admissions

    Proportion of subjects admitted to the hospital for HF exacerbations at any time point during the study

    Measured: 24 months

  2. Six-minute Walk Test

    Subject performance during six-minute walk test at 12 months after LVAD implantation

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jul 2021
  2. Study start31 Mar 2025 (estimated)
  3. Primary completion1 Sep 2026 (estimated)
  4. Study completion1 Sep 2026 (estimated)

Why it stopped: Did not receive funding from sponsor

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04977310
Sponsor's protocol ID
IRB_00143654
Status last verified
Nov 2024
First submitted
15 Jul 2021
Last updated
16 Dec 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing CardioMEMS in people with Heart Failure, run by STAVROS G DRAKOS at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 16 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of subjects that meet explantation criteria by month 12 post-LVAD implantation, have LVAD explanted and retain left ventricular ejection fraction >=45% at 12 months post-LVAD weaning (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in